Important data from the ADAPTcycle trial on early endocrine response in HR+/HER2- presented at #SABCS2023 by PD Dr. med. Oleg Gluz ! Endocrine Response Assessment will also be implementes in the ESMO guidelines beginning of 2024 as a simple and effective tool helping to make treatment decisions for patients with early breast cancer!
